CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions

J Neuroinflammation. 2024 Aug 19;21(1):206. doi: 10.1186/s12974-024-03202-8.

Abstract

Since its detection in the brain, the cannabinoid receptor type 2 (CB2) has been considered a promising therapeutic target for various neurological and psychiatric disorders. However, precise brain mapping of its expression is still lacking. Using magnetic cell sorting, calibrated RT-qPCR and single-nucleus RNAseq, we show that CB2 is expressed at a low level in all brain regions studied, mainly by few microglial cells, and by neurons in an even lower proportion. Upon lipopolysaccharide stimulation, modeling neuroinflammation in non-sterile conditions, we demonstrate that the inflammatory response is associated with a transient reduction in CB2 mRNA levels in brain tissue, particularly in microglial cells. This result, confirmed in the BV2 microglial cell line, contrasts with the positive correlation observed between CB2 mRNA levels and the inflammatory response upon stimulation by interferon-gamma, modeling neuroinflammation in sterile condition. Discrete brain CB2 expression might thus be up- or down-regulated depending on the inflammatory context.

Keywords: Cannabinoid receptor type 2; Endocannabinoid system; Microglia; Neuroinflammation.

MeSH terms

  • Animals
  • Brain* / metabolism
  • Gene Expression Regulation / drug effects
  • Inflammation / metabolism
  • Inflammation / pathology
  • Lipopolysaccharides* / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL*
  • Microglia* / metabolism
  • Neuroinflammatory Diseases / metabolism
  • Receptor, Cannabinoid, CB2* / biosynthesis
  • Receptor, Cannabinoid, CB2* / genetics
  • Receptor, Cannabinoid, CB2* / metabolism

Substances

  • Receptor, Cannabinoid, CB2
  • Lipopolysaccharides
  • Cnr2 protein, mouse